HBSP (USA)
-
El imperativo de la sustentabilidad
Lubin, David A.; Esty, Daniel C.Article HBS-R1005AService and Operations ManagementLos ejecutivos saben que la forma en que responden al reto de la sostenibilidad afectará profundamente a la competitividad de sus organizaciones - y tal vez incluso su supervivencia. Sin embargo, la mayoría están luchando con la forma de integrar los esfuerzos ambientales en sus estrategias de negocio. Muchos tienen una mezcolanza de las iniciativas verdes, pero sin visión o plan general. El problema no es que no ven la sostenibilidad como una cu...Starting at €8.20
-
The Sustainability Imperative
Lubin, David A.; Esty, Daniel C.Article HBS-R1005A-EService and Operations ManagementExecutives know that how they respond to the sustainability challenge will profoundly affect the competitiveness of their organizations - and perhaps even their survival. Yet most are struggling with how to integrate environmental efforts into their core business strategies. Many have a hodgepodge of green initiatives but no overarching vision or plan. The problem is not that they don't see sustainability as a strategic issue. Rather it's that th...Starting at €8.20
-
Corning: 156 Years of Innovation
Bowen, H. Kent; Purrington, CourtneyCase HBS-608108-EService and Operations ManagementThe executive team at Corning has committed to double the rate of new business creation per decade, while at the same time growing the company's current businesses, including glass substrates for LCD displays. Their strategy, built on more than 150 years of successful innovation, is to invent "keystone components" which uniquely enable other companies' products and earn high margins from its proprietary technology. As part of the company's missio...Starting at €8.20
-
Novartis AG: Science-Based Business
Bowen, H. Kent; Purrington, CourtneyCase HBS-608136-EService and Operations ManagementNovartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007, corporate R&D spending was $6.43B, or almost 17% of net sales. Novartis executive leaders believe in scientific progress and that large-scale investments in science will therefore r...Starting at €8.20